Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS

$125m Upfront For InnoCare

 
• By Andrew McConaghie and Brian Yang
  
Biogen
Biogen wants to stay competitive in MS, and sees BTK inhibitors a potentially key to the field's future. • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip